Does airway colonization cause systemic inflammation in bronchiectasis?;Bronşektazide hava yolu kolonizasyonu sistemik inflamasyona neden olur mu?

Tuberkuloz ve Toraks

Volumn 59, Issue 4, 2011, Pages 340-347

  Ergan Arsava, Begüm ^a   Çöplü, Lütfi ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bronchiectasis; C reactive protein; Colonization; Fibrinogen; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 8; LEPTIN; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; BIOLOGICAL MARKER;

ADULT; AIRWAY COLONIZATION; ARTICLE; BRONCHIECTASIS; CILIARY DYSKINESIA; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOGEN BLOOD LEVEL; HAEMOPHILUS INFLUENZAE; HUMAN; INFLAMMATION; LABORATORY TEST; LEUKOCYTE COUNT; LUNG FUNCTION TEST; MALE; MICROBIAL COLONIZATION; MICROBIOLOGICAL EXAMINATION; MORAXELLA CATARRHALIS; PATHOGENESIS; SPUTUM EXAMINATION; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC INFLAMMATION; TUBERCULOSIS; BACTERIUM; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; SPUTUM;

ADULT; BACTERIA; BIOLOGICAL MARKERS; BRONCHIECTASIS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; SPUTUM;

EID: 84857157534     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: 10.5578/tt.2934     Document Type: Article

References (35)

1. Cole PJ. Bronchiectasis. In: Brewis RAL, Corrin B, Geddes DM, Gibson GJ (eds). Respiratory Medicine. 2nd. London: WB Saunders, 1995: 1286-317.
2. Fraser RS, Colman N, Müller NL, Pare PD. Bronchiectasis and other bronchial abnormalities. In: Fraser RS, Müller NL, Colman N, Pare PD (eds). Fraser and Pare's Diagnosis of Diseases of the Chest. 4th ed. Philadelphia: WB Saunders, 1999: 2265-86.
3. Tsang KW, Tipoe GL. Bronchiectasis: not an orphan disease in the East. Int J Tuberc Lung Dis 2004; 8: 691-702.
4. O'Donnell AE. Bronchiectasis. Chest 2008; 134: 815-23.
5. Cole PJ. Inflammation: a two edged-sword- The model of bronchiectasis. Eur J Respir Dis 1986; 147(Suppl): 6-15.
6. Barker AF. Bronchiectasis. N Engl J Med 2002; 346: 1383-93.
7. Tsang KW, Ho PL, Lam WK, Ip MS, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998; 158: 723-7.
8. Gaga M, Bentley AM, Humbert M, Barkans J, O'Brien F, Wathen CG, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53: 685-91.
9. Angrill J, Agustí C, De Celis R, Filella X, Rañó A, Elena M, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164: 1628-32.
10. Tsang KW, Chan K, Ho P, Zheng L, Ooi GC, Ho JC, et al. Sputum elastase in steady-state bronchiectasis. Chest 2000; 117: 420-6.
11. Zheng L, Tipoe G, Lam WK, Ho JC, Shum I, Ooi GC, et al. Endothelin-1 in stable bronchiectasis. Eur Respir J 2000; 16: 146-9.
12. Fuschillo S, de Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008; 31: 396-406.
13. Frieri M. Inflammatory issues in allergic rhinitis and asthma. Allergy Asthma Proc 2005; 26: 163-9.
14. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-80.
15. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Dowling RB, Cole PJ, et al. Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998; 12: 820-4.
16. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995; 165: 261-7.
17. Standardized lung function testing: Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 1-100.
18. Angrill J, Agustí C, de Celis R, Rañó A, Gonzalez J, Solé T, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15-9.
19. Pye A, Stockley RA, Hill SL. Simple method for quantifying viable bacterial numbers in sputum. J Clin Pathol 1995; 48: 719-24.
20. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132: 1565-72.
21. Cano NJ, Pichard C, Roth H, Court-Fortuné I, Cynober L, Gérard-Boncompain M, et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004; 126: 540-6.
22. Miszkiel KA, Wells AU, Rubens MB, Cole PJ, Hansell DM. Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. Thorax 1997; 52: 260-4.
23. Ho PL, Chan KN, Ip MS, Lam WK, Ho CS, Yuen KY, et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998; 114: 1594-8.
24. Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996; 9: 1601-4.
25. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10: 1754-60.
26. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005; 128: 739-45.
27. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210-5.
28. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinically stable COPD. Eur Respir J 2004; 23: 685-91.
29. Groenewegen KH, Postma DS, Hop WC, Wielders PL, Schlösser NJ, Wouters EF; COSMIC Study Group. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008; 133: 350-7.
30. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ, Carratalá A, Yago M, et al. The association between bronchiectasis, systemic inflammation, and tumor necrosis factor alpha. Arch Bronconeumol 2008; 44: 8-14.
31. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008.
32. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007; 131: 1557-66.
33. Vernooy JH, Drummen NE, van Suylen RJ, Cloots RH, Möller GM, Bracke KR, et al. Enhanced pulmonary leptin expression in patients with severe COPD and asymptomatic smokers. Thorax 2009; 64: 26-32.
34. Antoniu SA. Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease. Biomarkers 2010; 15: 97-103.
35. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-5.